A review of chimeric antigen receptor T-cells in lymphoma

Anderson, Jennifer K.; Mehta, Amitkumar

doi:10.1080/17474086.2019.1629901

Cited by 11 publications

(4 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunotherapy infusing genetically modified T cells have altered the landscape of cancer treatment with the promise of complete and durable responses in leukemia [30,31]. The manufacture of genetically modified cells as drugs has given birth to a completely new set of challenges [32].…”

Section: Discussionmentioning

confidence: 99%

Phasetime: Deep Learning Approach to Detect Nuclei in Time Lapse Phase Images

Yuan

Rezvan

et al. 2019

JCM

View full text Add to dashboard Cite

Time lapse microscopy is essential for quantifying the dynamics of cells, subcellular organelles and biomolecules. Biologists use different fluorescent tags to label and track the subcellular structures and biomolecules within cells. However, not all of them are compatible with time lapse imaging, and the labeling itself can perturb the cells in undesirable ways. We hypothesized that phase image has the requisite information to identify and track nuclei within cells. By utilizing both traditional blob detection to generate binary mask labels from the stained channel images and the deep learning Mask RCNN model to train a detection and segmentation model, we managed to segment nuclei based only on phase images. The detection average precision is 0.82 when the IoU threshold is to be set 0.5. And the mean IoU for masks generated from phase images and ground truth masks from experts is 0.735. Without any ground truth mask labels during the training time, this is good enough to prove our hypothesis. This result enables the ability to detect nuclei without the need for exogenous labeling.

show abstract

Section: Discussionmentioning

confidence: 99%

Phasetime: Deep Learning Approach to Detect Nuclei in Time Lapse Phase Images

Yuan

Rezvan

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…The major toxicities associated with current CAR-T therapy include cytokine release syndrome (CRS), immune effector cellassociated neurotoxicity syndrome (ICANS), and on-target/offtumor toxicity (61)(62)(63). CRS is caused by the generation of massive inflammatory cytokines, such as IL-6, IL-10, IL-2, and TNFa, after CAR-T cell treatment.…”

Section: Barriers To Current Car-t Cell Therapymentioning

confidence: 99%

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy

et al. 2022

View full text Add to dashboard Cite

Chimeric antigen receptor T cell (CAR-T cell) therapy has shown impressive success in the treatment of hematological malignancies, but the systemic toxicity and complex manufacturing process of current autologous CAR-T cell therapy hinder its broader applications. Universal CAR-T cells have been developed to simplify the production process through isolation and editing of allogeneic T cells from healthy persons, but the allogeneic CAR-T cells have recently encountered safety concerns, and clinical trials have been halted by the FDA. Thus, there is an urgent need to seek new ways to overcome the barriers of current CAR-T cell therapy. In-vivo CAR-T cells induced by nanocarriers loaded with CAR-genes and gene-editing tools have shown efficiency for regressing leukemia and reducing systemic toxicity in a mouse model. The in-situ programming of autologous T-cells avoids the safety concerns of allogeneic T cells, and the manufacture of nanocarriers can be easily standardized. Therefore, the in-vivo induced CAR-T cells can potentially overcome the abovementioned limitations of current CAR-T cell therapy. Here, we provide a review on CAR structures, gene-editing tools, and gene delivery techniques applied in immunotherapy to help design and develop new in-vivo induced CAR-T cells.

show abstract

“…This therapy involves CAR-T cells derived from patients' T cells with an additional insertion of the chimeric antigen receptor (CAR) gene to enhance tumor cell recognition [216]. CAR-T cells targeting CD19 is the first CAR-T cell therapy approved by the US FDA for the treatment of B cell lymphoma [217]. CAR consists of an extracellular antigen recognition domain, a transmembrane region, and an intracellular signal domain [218].…”

Section: Combinations Of Ovs and Car-t Cell Therapiesmentioning

confidence: 99%

Development of oncolytic virotherapy: from genetic modification to combination therapy

et al. 2020

View full text Add to dashboard Cite

Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

show abstract

A review of chimeric antigen receptor T-cells in lymphoma

Cited by 11 publications

References 64 publications

Phasetime: Deep Learning Approach to Detect Nuclei in Time Lapse Phase Images

Phasetime: Deep Learning Approach to Detect Nuclei in Time Lapse Phase Images

In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy

Development of oncolytic virotherapy: from genetic modification to combination therapy

Contact Info

Product

Resources

About